Insulin degludec/liraglutide ranks highest for HbA1c reduction with SUCRA value of 89.4%
Comparing Combination Diabetes Drugs for Blood Sugar Control
This network meta-analysis evaluated 12,815 patients with type 2 diabetes to compare fixed-ratio combination products and their individual c…
A review of 12,815 patients found that insulin degludec/liraglutide may be best for lowering blood sugar, but has more side effects than oth…
GLP-1 receptor agonists show greater weight loss in women than men across multiple trials
Women Lose More Weight on GLP-1 Drugs Than Men Do
This systematic review and meta-analysis examined weight changes among adults with obesity, diabetes, or cardiovascular disease treated with…
• Women lose 11% weight versus 7% for men on these drugs • Helps adults using Wegovy Ozempic and similar weight loss medications • Works sam…
Meta-analysis finds GLP-1RA plus SGLT2i reduces UACR in type 2 diabetes with kidney disease
Combining two diabetes drugs protects kidneys better than using just one alone
This systematic review and meta-analysis of 1974 adults with type 2 diabetes and diabetic kidney disease found that combination therapy with…
Combining two common diabetes drugs offers better kidney protection than taking just one alone for people with type 2 diabetes
GLP-1 receptor agonists associated with lower mortality in HFrEF on GDMT
Heart Failure Patients Cut Death Risk With Common Diabetes Drug
In a retrospective, multicenter cohort study of 1,518 adults with HFrEF on guideline-directed therapy, GLP-1 receptor agonist use was associ…
Adding a common diabetes medication to standard heart failure treatment may significantly lower death rates.
Narrative review assesses GLP-1 receptor agonists versus insulin for steroid-induced hyperglycemia and diabetes
A Common Medication Side Effect May Have a Surprising New Solution
This narrative review evaluates the efficacy and safety of glucocorticosteroid-induced hyperglycemia (SIH) and steroid-induced diabetes (SID…
Doctors are exploring a new way to protect patients from the dangerous blood sugar spikes caused by essential steroid medications.
Observational EHR study suggests GLP-1 RA may have lower risk than SGLT2i for HF outcomes
Observational study links GLP-1 RA to lower risk than SGLT2i in heart failure patients
An observational study using real-world EHR data from Stony Brook University Hospital compared GLP-1 RAs to SGLT2 inhibitors in patients wit…
In heart failure patients, GLP-1 receptor agonists showed a lower risk of death or hospitalization compared to SGLT2 inhibitors over one yea…
GLP-1RAs reduce MACE risk in Asian and White adults with diabetes or overweight
Do heart benefits from diabetes drugs work equally well across different races?
A meta-analysis of 74,703 adults with type 2 diabetes or overweight/obesity found GLP-1RAs reduced MACE risk versus placebo.
Diabetes drugs protect hearts in Asian and White adults, but the benefit for Black adults remains unclear due to small study numbers.
GLP-1 Receptor Agonist Use in Wolfram Syndrome Shows No Glycemic or BMI Benefit, Common GI Effects
Can diabetes drugs help Wolfram syndrome? A new study looks at real-world use
A retrospective cohort study of 84 participants with genetically confirmed Wolfram syndrome and insulin-dependent diabetes found 35% had rec…
Doctors prescribed diabetes drugs to 35% of rare Wolfram syndrome patients, but records show no improvement in blood sugar, weight, or slowi…
Lixisenatide shows no effect on arterial stiffness in type 2 diabetes with chronic kidney disease
Study finds diabetes drug lixisenatide did not improve artery stiffness in kidney disease patients
A single-center, proof-of-concept randomized controlled trial in 90 people with type 2 diabetes and chronic kidney disease found that 24 wee…
A diabetes drug did not soften arteries in people with kidney disease, showing no improvement in a key heart risk factor after 24 weeks of t…